Parameter
| Biomarker | Angiopoietin-like protein 3 (ANGPTL3) | Full name | Angiopoietin-like protein 3 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Human ANGPTL3: C₂₉₈H₄₇₄N₈₄O₉₀S₂ | Molecular Weight | ~66.4 kDa | Core Functional Dimensions | Regulation of lipoprotein metabolism |
| Disease | Metabolic Associated Fatty Liver Disease (MASLD) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Serum (ELISA, mass spectrometry), hepatocytes (proteomics) | ||
| Pathobiological Mechanisms | ANGPTL3 deficiency alters lipoprotein lipidome, decreases CE and TG, increases PUfas associated lipids, and improves liver fat | ||||
| Clinical Availability Status | In the research phase, inhibitors (such as Evinacumab) are under clinical study | ||||
| Notes and Dynamics | It is a potential therapeutic target for metabolic MASLD, and the clinical research prospect of inhibitors is broad | ||||